These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 21958852

  • 1. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD.
    Nucl Med Biol; 2012 Jan; 39(1):23-34. PubMed ID: 21958852
    [Abstract] [Full Text] [Related]

  • 2. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 3. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF, Reist CJ, Bigner DD, Zalutsky MR.
    Cancer Res; 2000 Aug 15; 60(16):4453-60. PubMed ID: 10969792
    [Abstract] [Full Text] [Related]

  • 4. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.
    J Immunother Cancer; 2019 May 29; 7(1):142. PubMed ID: 31142380
    [Abstract] [Full Text] [Related]

  • 5. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2010 Oct 29; 37(7):741-50. PubMed ID: 20870149
    [Abstract] [Full Text] [Related]

  • 6. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X, Pastan I, Bigner DD, Chandramohan V.
    Receptors Clin Investig; 2016 Oct 29; 3(4):. PubMed ID: 28286803
    [Abstract] [Full Text] [Related]

  • 7. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
    Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, Bigner DD.
    Int J Cancer; 2000 Dec 15; 88(6):962-9. PubMed ID: 11093822
    [Abstract] [Full Text] [Related]

  • 8. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2006 Jan 15; 33(1):101-10. PubMed ID: 16459265
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2004 Oct 15; 31(7):909-19. PubMed ID: 15464393
    [Abstract] [Full Text] [Related]

  • 10. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2002 Jan 15; 29(1):1-11. PubMed ID: 11786270
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.
    Takasu S, Takahashi T, Okamoto S, Oriuchi N, Nakayashiki N, Okamoto K, Muramatsu H, Hayashi T, Nakahara N, Mizuno M, Wakabayashi T, Higuchi T, Endo K, Kozaki K, Miyaishi O, Saga S, Ueda R, Yoshida J, Yoshikawa K.
    J Neurooncol; 2003 Jul 15; 63(3):247-56. PubMed ID: 12892230
    [Abstract] [Full Text] [Related]

  • 12. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Appl Microbiol Biotechnol; 2017 Apr 15; 101(7):2747-2766. PubMed ID: 28013405
    [Abstract] [Full Text] [Related]

  • 13. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1995 Oct 01; 55(19):4375-82. PubMed ID: 7671250
    [Abstract] [Full Text] [Related]

  • 14. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
    Hens M, Vaidyanathan G, Welsh P, Zalutsky MR.
    Nucl Med Biol; 2009 Feb 01; 36(2):117-28. PubMed ID: 19217523
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD.
    Clin Cancer Res; 1999 Jun 01; 5(6):1539-49. PubMed ID: 10389943
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR.
    Cancer Res; 1996 Nov 01; 56(21):4970-7. PubMed ID: 8895752
    [Abstract] [Full Text] [Related]

  • 20.
    Chopra A.
    ; 2004 Nov 01. PubMed ID: 21348052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.